Obesity causes a number of changes, including an increase in volume of distribution and
changes in hepatic metabolism and renal excretion. Several antibiotics have sufficient data …

Background The prevention of healthcare-associated infections (HCAIs) is a major goal in
modern healthcare. Intrinsic, patient-related factors may contribute to the risk of HCAIs. Aim …

Introduction: Identifying the optimized dosing regimen and algorithm is critical in the
development of antibiotics. Suboptimal regimens and inappropriate choice of drug give rise …

The study objective was to evaluate the population pharmacokinetics and
pharmacodynamics of piperacillin and tazobactam administered by prolonged infusion in …

Objectives: Obesity may alter the pharmacokinetics of β-lactams. The goal of this study was
to evaluate if and why serum concentrations are inadequate when standard β-lactam …

Purpose The development and use of a decision support tool to help formulate
recommendations for dosing of commonly prescribed medications in critically ill obese …

Recognizing obesity-related pharmacokinetic and pharmacodynamic alterations is important
in treating obese patients with pneumonia. Studies that evaluate such alterations and …

Study Objective To evaluate the steady‐state pharmacokinetic and pharmacodynamic
parameters of piperacillin in morbidly obese, surgical intensive care patients. Design Open …

Abstract Background and Objective Standard piperacillin–tazobactam (PT) dosing may be
suboptimal in obesity, but high-dose regimens have not been studied. We prospectively …

Background Obesity is on course to overtake being underweight as a global disease
burden. Obesity alters antibacterial pharmacokinetics (PK) and pharmacodynamics (PD) …